Two Princeton University studies are opening important new windows into understanding an untreatable group of common genetic disorders known as RASopathies that are characterized by distinct facial features, developmental delays, cognitive impairment and heart problems. The findings could help point the way toward personalized precision therapies for these conditions. Although not widely known, RASopathies are among the most common genetic disorders, affecting approximately one child out of 1,000. RASopathies are caused by mutations within the RAS pathway, a biochemical system cells use to transmit information from their exterior to their interior. https://askpinkiepiesolutions.tumblr.com/ "Human development is very complex and it's amazing that it goes right so often. However, there are certain cases where it does not, as with RASopathies," said Granton Jindal, co-lead author of the two studies. Both Jindal and the other co-lead author, Yogesh Goyal, are graduate students in the Department of Chemical and Biological Engineering and the Lewis-Sigler Institute for Integrative Genomics (LSI). Jindal and Goyal do their thesis research in the lab of Stanislav Shvartsman, professor of chemical and biological engineering and LSI. "Our new studies are helping to explain the mechanisms underlying these disorders," Jindal said. These studies were published this year, one in the Proceedings of the National Academy of Sciences (PNAS) and the other in Nature Genetics online. The researchers made the discoveries in zebrafish and fruit flies -- animals commonly used as simplified models of human genetics and Jindal and Goyal's specialties, respectively. Due to the evolutionary similarities in the RAS pathway across diverse species, changes in this pathway would also be similar. Thus, it is likely that significant parts of findings in animals would apply to humans as well, although further research is needed to confirm this. The first paper published Jan. 3 in PNAS presented a way to rank the severity of different mutations involved in RASopathies. The researchers introduced 16 mutations one at a time in developing zebrafish embryos. As each organism developed, clear differences in the embryos' shapes became evident, revealing the strength of each mutation. The same mutant proteins produced similarly varying degrees of defects in fruit flies. Some of the mutations the researchers tested were already known to be involved in human cancers. The researchers noted that these cancer-related mutations caused more severe deformations in the embryos, aligning with the medical community's ongoing efforts to adapt anti-cancer compounds to treat RASopathies. https://ccharleswood.tumblr.com/ "Until now, there was no systematic way of comparing different mutation severities for RASopathies effectively," Goyal said. Jindal added, "This study is an important step for personalized medicine in determining a diagnosis to a first approximation." The study therefore suggested a path forward to human diagnostic advances, potentially enabling health care professionals to offer better diagnoses and inform caretakers about patients' disease progression. The study went further and examined the use of an experimental cancer-fighting drug being investigated as a possible way to treat RASopathies. The researchers demonstrated that the amount of medication necessary to correct the developmental defects in the zebrafish embryos corresponded with the mutation's severity -- more severe mutations required higher dosages. The more recent paper, published online by Nature Genetics Feb. 6, reports an unexpected twist in treatment approach to some RASopathies. Like all cellular pathways, the RAS pathway is a series of molecular interactions that changes a cell's condition. Conventional wisdom has held that RASopathies are triggered by overactive RAS pathways, which a biologist would call excessive signaling. The Nature Genetics study, however, found that some RASopathies could result from insufficient signaling along the RAS pathway in certain regions of the body. This means that drugs intended to treat RASopathies by tamping down RAS pathway signaling might actually make certain defects worse. Source: https://www.sciencedaily.com/releases/2017/02/170207142722.htm

Sunday, May 10, 2026

Topamax (topiramate): Uses, How It Works, And What To Expect

Topamax is a medication used in the treatment of conditions falling under seizure and epilepsy treatment. Its active pharmaceutical ingredient is topiramate, which has been studied in clinical settings and has an established record of use in appropriate patient populations. Understanding what this medication does, how it is taken, and what results are realistic helps patients make informed decisions alongside their healthcare providers. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by sudden, abnormal electrical activity in the brain. Seizures vary widely in their manifestation, from brief lapses in consciousness lasting only seconds to full convulsive episodes involving the entire body. The specific seizure type, the region of the brain involved, and the underlying cause of the epilepsy are all important factors in determining the most appropriate treatment approach. The therapeutic action of topiramate is tailored to the biological mechanisms underlying the conditions it is used to treat. By targeting specific receptors, enzymes, or pathways, it produces changes that reduce symptoms and in some cases modify the course of disease. Detailed clinical information about Topamax can be found at https://mednewwsstoday.com/seizures/topamax-topiramate/, which outlines indications, dosing guidelines, and important safety information. Most patients tolerate Topamax well, though like any medication it can cause side effects in some individuals. Common side effects are typically mild and may resolve once the body adjusts to the medication. Serious adverse effects are less common but should be reported to a healthcare provider promptly. Patients with specific health conditions or those taking multiple medications should review potential interactions before starting Topamax. Resources covering the full range of therapies available for seizure and epilepsy treatment are available at https://mednewwsstoday.com/seizures/. Comparing medications in terms of their effectiveness, safety, and practical considerations helps patients and caregivers engage in productive conversations with their healthcare team.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)